This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
the duration of the effectiveness of the intervention;
HIV prevalence among males in the community;
HIV prevalence among females in the community; the probability of transmission for receptive vaginal intercourse; the probability of transmission for insertive vaginal intercourse; the probability of transmission for receptive anal intercourse; the probability of transmission for insertive anal intercourse; and the effectiveness of condoms.
Study designs and other criteria for inclusion in the review
The model mainly used the data from a single randomised controlled trial of the intervention. The review also included other studies. The inclusion criteria for the studies used in the review were not reported.
Sources searched to identify primary studies
Not reported.
Criteria used to ensure the validity of primary studies
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
A total of 18 primary studies were included in the review.
Methods of combining primary studies
Investigation of differences between primary studies
Not reported. However, the authors did state that two studies were excluded from the review because the patient population (homeless and gay people) was irrelevant to the study.
HIV prevalence among females in the community was 0.6% (0.1%, 2.5%); the probability of transmission for receptive vaginal intercourse was 0.0014 (0.0010, 0.0018); the probability of transmission for insertive vaginal intercourse was 0.0006 (0.0004, 0.0008); the probability of transmission for receptive anal intercourse was 0.02 (0.015, 0.025); the probability of transmission for insertive anal intercourse was 0.0006 (0.0004, 0.0008); and the condom effectiveness was 90% for the intervention group and 80% for the control group (80%, 90%).
Methods used to derive estimates of effectiveness
The estimates of effectiveness for the duration of effectiveness and the probability of transmission for insertive anal intercourse were derived from the authors' assumptions.
Estimates of effectiveness and key assumptions
The duration of effectiveness (12 months) and the probability of transmission for insertive anal intercourse (0.0006) were estimated, rather than obtained from the published literature. These data augmented the data used in the review for the model. The key assumptions used in these estimates were not reported.
Measure of benefits used in the economic analysis
The measures of benefit used in the economic analysis were the number of HIV infections averted and the number of quality-adjusted life-years (QALYs). The number of infections averted was defined as the difference between the expected number of infections and those reported at follow-up in a published study. The estimated number was derived from the sexual behaviour reported by the participants at baseline. A mathematical model was used to translate the reported mean changes in sexual behaviour into an estimate of the number of infections expected.
The change in QALYs was estimated for each infection averted. A published analysis suggested that a person who was infected with HIV at age 15 would lose a total of 34.21 QALYs by 65 years of age. This estimate assumed that the person received standard medical treatment. The health state valuation method was not reported.
Direct costs
The resource quantities and the unit costs were reported separately. The authors reported that all the direct costs were included, regardless of who paid or benefited. The direct costs were related to personnel (sessions, training, recruiting), staff transportation (sessions, training), materials, facilities, and the participants. The quantities and costs were estimated using actual data from a published study. The authors did not report the source of the unit cost data. However, they did report the total costs of the intervention and the average cost per participant. The time horizon for the study was lifetime. All the costs were discounted at an annual rate of 3% in the base-case analysis. The cost data referred to 1997. The costs were estimated from a study conducted in 1988, and were adjusted for inflation using the US Federal Government's Consumer Price Index.
Statistical analysis of costs
Currency US dollars ($) . No currency conversions were reported.
Sensitivity analysis
One-way sensitivity analyses were conducted for the following input parameters for the model: the probability of transmission (plus and minus 25%); the condom effectiveness (80%, 90%); the duration of the intervention effectiveness (6 months, 18 months); a subsample of adolescents who were sexually active at baseline; the treatment scenario (low cost, high cost); the discount rate (0%, 5%); and the intervention costs (excluding training costs, excluding training and participant costs).
Estimated benefits used in the economic analysis
For the full-study sample, a total of 0.008 infections were averted and 0.106 QALYs were saved.
For the subsample of adolescents who were classified as being sexually active at baseline, a total of 0.006 infections were averted and 0.080 QALYs were saved.
Cost results
The total cost of the intervention was $7,548 for the full sample. This corresponded to a cost of approximately $89 per participant.
The total cost of the intervention was $3,374 for the subsample of adolescents who were classified as being sexually active at baseline. This corresponded to a cost of approximately $89 per participant.
